Is your organization missing from this list? Reach out to Danielle Cann, Strategic Alliance Partnership Coordinator, to learn more about the complimentary strategic partnership program: dcann@mjhlifesciences.com
Becoming Familiar With Patients’ AEs is Essential, Says Expert
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC
Tivozanib Combo Yields Similar PROs to Monotherapy in Advanced Clear Cell RCC
Dose Reductions Possible for Tivozanib With and Without Nivolumab for RCC
Relacorilant/Nab-Paclitaxel May Increase PFS, OS in Ovarian Cancer
Osimertinib Sustains OS Improvement in EGFR-Mutant NSCLC
Elotuzumab/PVd Combo Elicits Response in Relapsed/Refractory MM
Camrelizumab Plus Rivoceranib Receives Second CRL in HCC